There is increasing attention to optimizing the predictive value of preclinical research—ensuring that studies are done rigorously and that data are reported transparently. The potential here is that some clinical trial failures may be avoidable by ensuring that the preclinical rationale for those trials is well developed. – Dr. John Porter, Program Director, Neurogenetics Cluster, NINDS
With this note, the NINDS has just posted a summary of their recent conference topic at their website, http://www.ninds.nih.gov/.
Read the NINDS Workshop Summary.
Read the NINDS Guidelines on “Improving the Quality of Preclinical and Clinical Research through Rigorous Study Design and Transparent Reporting”
